Arthneeti
CS

Clean Science

Q3 FY26Chemicals & Petrochemicals

Clean Science Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q3 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹822
Market cap₹8.8K Cr
P/E37.7
Updated26 Aug 2026
Read5 min read

The short version

Performance Chemical 1 plant started producing in-house hydroquinone and catechol; sales to start from February with growth expected in March FY '27. The company anticipates margin improvement and revenue growth by launching new products and maintaining disciplined capex cycles.

From Clean Science's Q3 FY26 earnings-call transcript · updated 26 Aug 2026.

Revenue & Sales Performance

  • Performance Chemical 1 plant started producing in-house hydroquinone and catechol; sales to start from February with growth expected in March FY '27.
  • Performance Chemical 2 plant commissioning delayed to May-June FY '27; revenue generation anticipated from Q4 FY '27.
  • HALS business showing strong growth, with 55% Y-o-Y volume increase; expected to sustain momentum in coming years.
  • New product commercialization (hydroquinone and catechol) will lower raw material costs and enhance margins.
  • Efforts ongoing to improve process efficiencies and bring more products online, aiming for volume growth and margin improvement.
  • Domestic and international demand expected to recover post current macroeconomic challenges.
  • Trade deal with Europe starting in FY '27 to potentially reduce tariffs (5.5%-12%), helping competitiveness against China.
  • Expanding export efforts (e.g., catechol exports to China starting February FY '27).
  • Overall growth and margin recovery expected over 5-year strategic horizon despite short-term uncertainties.

Profitability & Margins

See what Clean Science said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

- Hydroquinone and catechol plants were commercialized in December; customer trials ongoing. - Capex for Performance Chemical 2 is on plan; commercialization expected in Q1 FY '27 (around May-June). - Performance Chemical 2 will start generating staggered revenues from Q4 FY '27. - Performance Chemical 1 running at ~80% capacity utilization; expected revenue INR 260 crores in FY '27 (down from earlier estimate of INR 320 crores) due to reduced prices. - Capex investments amount to around INR 1.5 billion each for Performance Chemical 1 and 2. - The expansion of TBHQ and in-house production of hydroquinone expected to moderate raw material costs and improve margins. - Ongoing R&D to bring new products online and diversify product portfolio. - Total investment in subsidiary Clean Fino Chem Ltd. around INR 700 crores, with INR 150 crores infused in the last 9 months. Overall, capex activities continue with some delays but aligned to strategic growth plans.

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

5x potential
1Shiv Texchem
Rev 1Mar 2
2Yasho Industries
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Clean Science said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript provided does not explicitly mention the current or expected order book or pending orders for Clean Science and Technology Limited. However, relevant insights include: - Performance Chemical 2 plant commercialisation is expected in Q1 FY'27, with production delayed to May from the initially planned March. - New products, including hydroquinone and catechol, were commercialized in December, with customer trials ongoing and exports commencing from February. - Demand challenges are noted due to tariffs and Chinese competition affecting sales volume, but the company aims to retain market share. - New samples of Pharma intermediate DHDT have been sent to customers; outcomes awaited in coming weeks. - The Europe-India trade deal expected to positively impact business beginning in 2027 due to tariff reductions. No specific quantified details on current or pending orders or order book values are provided in the transcript.

Clean Science — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹249 Cr, net profit ₹58 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Clean Science & Technology Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

  • Aether Industries Ltd (Q3 FY26)

    The company currently services Baker Hughes with 8 products in commercial production (Site 4) generating a run rate of INR 60 crores this quarter. Key concall…

  • Kesar Petroproducts Ltd (Q3 FY26)

    Export markets constitute about 40% of sales, served through 7-8 distributors across geographies. Key concall takeaways from Kesar Petroprod.'s Q3 FY26…

  • Tata Chemicals Ltd (Q3 FY26)

    Indian salt capacity expansion of 210 KT per annum with INR 515 crore investment is underway to meet growing demand. Key concall takeaways from Tata…

  • Fine Organic Industries Ltd (Q3 FY26)

    Investment of approximately INR 700-750 crores for Phase 1. Key concall takeaways from Fine Organic's Q3 FY26 earnings call — and how it ranks against sector…

Compare:vs Solar Industries India Ltdvs Pidilite Industries Ltdvs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Clean Science Q3 FY26 results?

Performance Chemical 1 plant started producing in-house hydroquinone and catechol; sales to start from February with growth expected in March FY '27. The company anticipates margin improvement and revenue growth by launching new products and maintaining disciplined capex cycles.

What is Clean Science share price analysis?

Clean Science currently shows a neutral. The stock trades at a P/E of 37.7 with a market cap of ₹8,774 Cr. Investors should review the full earnings analysis for detailed insights.

Is Clean Science planning capital expenditure?

Hydroquinone and catechol plants were commercialized in December; customer trials ongoing. - Capex for Performance Chemical 2 is on plan; commercialization expected in Q1 FY '27 (around May-June). - Performance Chemical 2 will start generating staggered revenues from Q4 FY '27. - Performance Chemical 1 running at ~80% capacity utilization; expected revenue INR 260 crores in FY '27 (down from earlier estimate of INR 320 crores) due to reduced prices. - Capex investments amount to around INR 1.5 billion each for Performance Chemical 1 and 2. - The expansion of TBHQ and in-house production of hydroquinone expected to moderate raw material costs and improve margins. - Ongoing R&D to bring new products online and diversify product portfolio. - Total investment in subsidiary Clean Fino Chem Ltd.

Keep Clean Science on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.